Modulation of cisplatin sensitivity and accumulation by interferon α‐2A in human squamous carcinoma cell lines

Vicram Gupta, Jitesh P. Jani, Erling O. Emerson, Bing H. Xu, Domenic Scalamogna, Hong Xia, Arthur Katoh, Howard A. Zaren, Shivendra V. Singh

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

This study was undertaken to elucidate the mechanism(s) of potentiation of cisplatin (CDDP) cytotoxicity by interferon α‐2a (IFN α‐2a) in human squamous carcinoma cell lines SCC‐25 and SCC‐4. IFN α‐2a treatment significantly increased the cytotoxicity of CDDP in both cell lines in a dose‐dependent manner. In SCC‐25 cells, the cytotoxicity of CDDP was increased by about 2‐ and 4‐fold, respectively, by treating the cells with 400 and 800 1U/ml IFN α‐2a. Sensitivity of SCC‐4 cells to CDDP was increased by about 3‐ and 7‐fold, respectively, by 400 and 800 1U/ml IFN α‐2a treatment. Drug uptake experiments revealed approximately 1.4‐ to 5‐fold higher platinum accumulation in IFN α‐2a‐treated cells as compared to respective controls. Cellular levels of glutathione (GSH) and GSH transferase, which have been suggested to be important determinants of tumor cell sensitivity to CDDP, were not altered by IFN α‐2a treatment in either of the cell lines. Northern blot analysis showed a moderate increase (about 30–40%) in the level of MT‐IIA mRNA by IFN α‐2a treatment in these cells. Our results suggest that IFN α‐2a‐mediated sensitization of SCC‐25 and SCC‐4 cell lines to CDDP in vitro may be due to an increase in intracellular platinum accumulation.

Original languageEnglish (US)
Pages (from-to)419-422
Number of pages4
JournalInternational Journal of Cancer
Volume63
Issue number3
DOIs
StatePublished - Nov 3 1995
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Modulation of cisplatin sensitivity and accumulation by interferon α‐2A in human squamous carcinoma cell lines'. Together they form a unique fingerprint.

Cite this